Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMEMSB2)

Drug Name	PMID25991433-Compound-Q1 Drug Info
Cross-matching ID	PubChem CID 56946834 TTD Drug ID DMEMSB2

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Mitogen-activated protein kinase (MAPK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GBL-310	DM2IFJQ	Keratosis	ED56	Phase 2	[2]
LTT462	DM94E6W	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
PF-07799544	DMAO10K	Aggressive cancer	2A00-2F9Z	Phase 1	[4]
PMID25991433-Compound-L2	DM58UO9	N. A.	N. A.	Patented	[1]
PMID25991433-Compound-L3	DM3LWUR	N. A.	N. A.	Patented	[1]
Bidentate ligands of Markush derivative 2	DM2QNMC	N. A.	N. A.	Patented	[5]
Bidentate ligands of Markush derivative 1	DMB08D3	N. A.	N. A.	Patented	[5]
PMID25991433-Compound-C3	DMSKWBE	N. A.	N. A.	Patented	[1]
PMID25991433-Compound-J6	DMOWULJ	N. A.	N. A.	Patented	[1]
PMID25991433-Compound-L	DM5U8WT	N. A.	N. A.	Patented	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting Jun N terminal kinase (JNK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AM-111	DM4E9PK	Neurological disorder	6B60	Phase 3	[6]
BGP-15	DMYDM68	Type-2 diabetes	5A11	Phase 2	[7]
CC-401	DMPMO6G	Solid tumour/cancer	2A00-2F9Z	Phase 2	[8]
CC-930	DMHVEGJ	Discoid lupus erythematosus	EB51.0	Phase 2	[9]
PMID25991433-Compound-O1	DMH073T	N. A.	N. A.	Patented	[1]
2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One	DMDN12L	Discovery agent	N.A.	Investigative	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Jun N terminal kinase (JNK)	TTR2TXZ	MK08_HUMAN; MK09_HUMAN; MK10_HUMAN	Inhibitor	[1]
Mitogen-activated protein kinase (MAPK)	TTVOE6D	NOUNIPROTAC	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
2	WO patent application no. 2010,0456,51, Methods for analyzing drug response.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2023. Adis Insight
5	Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jun;27(6):667-676.
6	The JNK inhibitor XG-102 protects against TNBS-induced colitis.PLoS One.2012;7(3):e30985.
7	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8	Signal integration by JNK and p38 MAPK pathways in cancer development.Nat Rev Cancer.2009 Aug;9(8):537-49.
9	In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism. Xenobiotica. 2015;45(6):465-80.
10	c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001 Jul;108(1):73-81.